<DOC>
	<DOCNO>NCT02449044</DOCNO>
	<brief_summary>This study assess safety long-term tolvaptan use patient previously enrol shorter-term Phase 3 study gather information natural history hyponatremia context tolvaptan therapy underlie disease state .</brief_summary>
	<brief_title>International , Multicenter , Study One-year , Open-label , Titrated Oral Tolvaptan Tablet Administration Patients With Chronic Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Age great equal 18 year . 2 . Ability provide inform consent assent . 3 . Prior successful participation tolvaptan hyponatremia trial termination evidence continue need desire therapy . A current medical condition longterm treatment aquaretic agent may present undue risk patient . Hyponatremia acute , reversible , artifactual due condition associate vasopressin excess likely respond aquaretic therapy . Hyponatremia due reversible medical condition therapy Conditions associate independent imminent risk morbidity mortality Conditions confound assessment endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Hyponatremia</keyword>
</DOC>